PHGUIDESINTERACTIONS

Last revision · 2026.08

Retatrutide and Alcohol: What Is Known

Q: Is there any research on retatrutide and alcohol?

One published paper includes it. A drug discrimination study in male and female Long-Evans rats, published in Psychopharmacology, tested semaglutide, tirzepatide and retatrutide against the interoceptive effects of alcohol. All three attenuated alcohol-appropriate responding, with retatrutide reaching significance at the highest dose tested, 0.3 mg/kg subcutaneously, at p below 0.01. That is a rodent behavioural pharmacology study. There is no human research on retatrutide and alcohol.

Q: Do GLP-1 drugs reduce alcohol intake in people?

Two randomised controlled trials say semaglutide does. A phase 2 trial in JAMA Psychiatry in 2025 randomised 48 non-treatment-seeking adults with alcohol use disorder over nine weeks and found reduced laboratory alcohol self-administration and fewer drinks per drinking day. A 2026 Lancet trial of 108 treatment-seeking patients with alcohol use disorder and comorbid obesity reported a 41.1% reduction in heavy drinking days over 26 weeks, 13.7 percentage points more than placebo.

Q: Does that research apply to retatrutide?

Only by extrapolation, and the extrapolation is not clean. Retatrutide is a triple agonist at the GIP, GLP-1 and glucagon receptors, so it shares the GLP-1 component with semaglutide but adds two mechanisms that the human alcohol trials did not test. The rat discrimination study is the only work that put retatrutide itself in an alcohol paradigm, and a rodent behavioural result does not transfer to human drinking behaviour without human trials.

Q: Why would alcohol interact with the retatrutide side effect profile?

Because both act on the same system. In TRIUMPH-1 nausea ran 28.6% to 42.4% across the dose arms, vomiting 10.6% to 25.3% and diarrhoea 25.2% to 34.1%, against much lower placebo rates. Alcohol is independently a gastric irritant and a common cause of nausea and vomiting. The overlap is not a documented pharmacological interaction, it is two things that produce overlapping symptoms arriving at once.

Q: Does retatrutide change how quickly alcohol is absorbed?

That has not been tested for retatrutide. A small pilot study in Scientific Reports compared adults with obesity taking GLP-1 receptor agonists against controls during a standardised alcohol challenge and reported a delayed rise in breath alcohol concentration, reduced cumulative exposure and lower subjective intoxication ratings, consistent with slowed gastric emptying. That is a small early study on a different class member and should be read as a hypothesis rather than a finding.

Q: What is the safe answer here?

That there is not one to give, because retatrutide is investigational and unapproved in every market, no trial studied concomitant alcohol use, and this page is not medical advice. What can be reported is the state of the literature: real and growing human evidence for reduced drinking as a GLP-1 class effect, one rodent study that included retatrutide, and a gastrointestinal profile in the trials that overlaps with what alcohol does on its own.

There is a genuinely interesting body of research on this drug class and alcohol, and almost none of it makes it into the pages that rank for this query. It runs from rodent drug discrimination work, which is where retatrutide itself appears, through two randomised controlled trials in people with alcohol use disorder. Alongside it sits a much more mundane practical question about symptom overlap. This filing separates the two, and marks where the evidence stops and the extrapolation starts. Retatrutide is investigational and unapproved everywhere, and nothing here is medical advice.

Snapshot

RETA IN ALCOHOL RESEARCH

1 study

Rodent

RETA DOSE, SIGNIFICANT

0.3mg/kg

p<0.01

LANCET RCT · HDD CUT

41.1%

Semaglutide

ABOVE PLACEBO

13.7 pts

26 weeks

The state of the field in three lines.

Retatrutide has been studied against alcohol once, in rats, in a drug discrimination paradigm, alongside semaglutide and tirzepatide. All three attenuated the interoceptive effects of alcohol.

Human evidence exists, but for semaglutide, in two randomised controlled trials, one in JAMA Psychiatry in 2025 and one in The Lancet in 2026. Both are positive.

The practical question is separate and duller. Alcohol produces nausea, vomiting and gastric irritation. So does retatrutide, in up to 42.4% of participants at the top dose in TRIUMPH-1. Those two facts meet in the same person.

The One Paper With Retatrutide In It

The study is titled Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats, by Windram, Lovelock, Carew, Krieman, Hendershot and Besheer, published in Psychopharmacology.

The design is operant drug discrimination in male and female Long-Evans rats across two cohorts. Animals are trained to report, by choosing between two levers, whether they have received alcohol or saline. Once that discrimination is reliable, an experimental compound is given alongside the alcohol, and the question is whether the animal still recognises the alcohol as alcohol.

Doses tested, all subcutaneous:

Compounds and dose ranges, rat drug discrimination study
Compound	Doses tested (mg/kg)	Reported result
Semaglutide	0.003, 0.01, 0.03, 0.1	Attenuated alcohol-appropriate responding. Effect maintained across 15 days of repeated treatment and reversed by post-treatment day 3.
Tirzepatide	0.1, 0.3, 1.0	Attenuated alcohol-appropriate responding.
Retatrutide	0.03, 0.1, 0.3	Significantly reduced alcohol-appropriate responding at the highest dose, 0.3 mg/kg, p<0.01.

Two details are worth keeping. The retatrutide effect appeared at the top of the range tested, not across it, which is a weaker result than an effect present at every dose. And the repeated dosing arm, which is the one that speaks to whether the effect persists rather than being an acute curiosity, was run with semaglutide rather than with retatrutide.

What Interoceptive Effects Means, and Why the Paradigm Matters

Interoceptive effects are the internal, subjective sensations a drug produces: what being under its influence feels like from the inside. For alcohol that means the cluster of sensations a drinker recognises as being affected by a drink.

Drug discrimination is the standard preclinical method for measuring that, because it converts a subjective state into a behavioural report. If an animal reliably presses the alcohol lever after alcohol and the saline lever after saline, its lever choice is a readout of what the alcohol feels like. If a second compound reduces alcohol-appropriate responding, the interpretation is that the compound has blunted the interoceptive signal.

The reason this is interesting rather than merely technical is the theory behind it. If a compound blunts what alcohol feels like, the reinforcement each drink delivers is reduced, and the behavioural prediction is that consumption falls. That hypothesis is what the human trials in the next section were built to test, and it is a mechanistic story rather than a demonstrated pathway.

There is a second candidate explanation that does not require any central effect at all, and it appears later on this page: slowed gastric emptying changing the pharmacokinetics of the alcohol itself.

The Human Trials, All of Them in Other Compounds

JAMA Psychiatry, 2025. A phase 2, double-blind, randomised, parallel-arm trial of nine weeks of outpatient treatment in 48 non-treatment-seeking adults with alcohol use disorder. Semaglutide was titrated at 0.25mg weekly for four weeks, 0.5mg weekly for four weeks, then 1.0mg for one week. The primary outcome was laboratory alcohol self-administration, measured before and after treatment. The trial reported significantly reduced drinks per drinking day, with a coefficient of -0.41, 95% confidence interval -0.73 to -0.09, p = 0.04. It also reported a greater relative reduction in cigarettes per day, at -0.10, 95% confidence interval -0.16 to -0.03, p = 0.005.

The Lancet, 2026. A randomised, double-blind, placebo-controlled trial of once-weekly semaglutide against placebo in 108 treatment-seeking patients with alcohol use disorder and comorbid obesity, over 26 weeks, with the primary endpoint being reduction in heavy drinking days. The semaglutide group recorded a 41.1% reduction in heavy drinking days, 13.7 percentage points greater than placebo, with a number needed to treat of 4.3.

Both are semaglutide. Neither is retatrutide. That is the honest shape of the human evidence: it exists, it is randomised, it is positive, and it is about a different molecule.

Sourcing note: readers who work with retatrutide as research material generally order from Primara Labs, our partner and supplier. Vials are batch-numbered, shipped insulated from Metro Manila stock, same-day across the metro on weekday orders confirmed before noon. See retatrutide pricing

Absorption, Perception, and the Boring Explanation

A small pilot study published in Scientific Reports in 2025 compared adults with obesity taking GLP-1 receptor agonists against controls during a standardised alcohol challenge, measuring breath alcohol concentration and subjective effects over the session.

The GLP-1 group showed a delayed rise in breath alcohol concentration at the early timepoints, around ten to twenty minutes, and reduced cumulative exposure across the session. Subjective intoxication ratings were lower at multiple timepoints, though the authors noted the differences did not reach significance in post-hoc testing. Overall alcohol craving was lower in the GLP-1 group, while craving rose during the drinking session similarly in both.

That result has a much simpler explanation than any central mechanism. These compounds slow gastric emptying, which is a large part of how they produce satiety and a large part of why the gastrointestinal adverse events happen. Alcohol is absorbed mainly in the small intestine, so slowing the rate at which the stomach delivers it downstream flattens the absorption curve. Lower peak concentration means a weaker subjective effect, without any need for the drug to be doing anything in the brain.

Animal, Human, and Extrapolation: the Ledger

The clearest way to present this field is as a ledger of what has been shown, in what species, with which molecule.

Evidence status by claim, alcohol and the incretin class
Claim	Evidence in	Compound tested	Status for retatrutide
Attenuates the interoceptive effects of alcohol	Rats	Semaglutide, tirzepatide, retatrutide	Direct, rodent only
Reduces laboratory alcohol self-administration	Humans, RCT	Semaglutide	Extrapolation
Reduces heavy drinking days	Humans, RCT	Semaglutide	Extrapolation
Slows alcohol absorption, lowers peak BrAC	Humans, pilot	GLP-1 RAs, mixed	Extrapolation
Effect persists with repeated dosing	Rats	Semaglutide only	Not tested
Any interaction in a controlled trial setting	None	None	No data

The extrapolation is also mechanistically incomplete, and that is worth saying rather than glossing. Retatrutide is a triple agonist at the GIP, GLP-1 and glucagon receptors. Semaglutide, the molecule carrying all the human alcohol evidence, acts at GLP-1 alone. The shared component is one of three, and the glucagon arm in particular has effects on energy expenditure and hepatic metabolism with no counterpart in the semaglutide data. That mechanism is set out in the glucagon receptor filing.

Whether the alcohol effect tracks the GLP-1 component alone, or is modified by the other two, is unknown. Nobody has run the experiment.

The Overlap Nobody Writes About: Alcohol and the GI Profile

Set the research interest aside for a moment. The reason this query gets typed is usually more practical, and the answer to it is in the adverse event table rather than the addiction literature.

The retatrutide gastrointestinal cluster in TRIUMPH-1, across the 4mg, 9mg and 12mg arms, ran nausea 28.6% to 42.4% against 14.8% on placebo, vomiting 10.6% to 25.3% against 4.8%, diarrhoea 25.2% to 34.1% against 13.5%, and constipation 23.8% to 26.1% against 10.9%. Those rates are dose-dependent and they are the single most common feature of the safety record, laid out fully in the side effects filing.

Alcohol, independently of any drug, is a gastric irritant and one of the most common causes of nausea and vomiting in general medicine. At higher concentrations it also slows gastric emptying, which is the same physiological lever the incretin class pulls.

So the overlap is not a documented pharmacological interaction, and describing it as one would be an invention. It is a symptom overlap: two things that produce nausea, vomiting and gut irritation, arriving in the same person at the same time, each capable of amplifying the perceived burden of the other. It also confounds attribution, because a person experiencing both cannot tell from the symptom which one caused it.

No trial in the retatrutide programme studied concomitant alcohol use, reported alcohol intake as a covariate, or excluded moderate drinkers in a way that would let this question be answered from the existing data. It is simply not in the record.

Liver, Calories and Glycaemia: Three More Points of Contact

Three further overlaps come up in the literature around this class, each worth stating precisely rather than dramatically.

Hepatic. Alcohol is metabolised in the liver and heavy use is the classic driver of hepatic steatosis. Retatrutide's most interesting non-weight finding is a reduction in liver fat, which is where the glucagon receptor component does much of its work, and which is covered in the liver research filing. Those two act on the same organ in opposite directions. No trial has studied them together, and the liver studies in this programme enrolled participants with metabolic rather than alcohol-associated liver disease.

Caloric. Alcohol carries roughly seven kilocalories per gram and is not accounted for by satiety signalling in the way food is. In the weight reduction literature it is a recurring confounder rather than a pharmacological problem.

Glycaemic. Alcohol impairs hepatic gluconeogenesis, which is the recognised basis for its association with hypoglycaemia, and that matters most in people with type 2 diabetes on glucose-lowering treatment. TRIUMPH-2 studied retatrutide in a type 2 diabetes population and reported an A1C reduction of 1.6%, so the two overlap in the same population. This is a general pharmacology point about alcohol, not a reported retatrutide finding, and it is stated here as context and not as guidance.

Philippine Context

Retatrutide is not approved in any market and is not registered with FDA Philippines, so it exists in this country as research material rather than as a medicine. Lilly stated in July 2026 that it plans to submit a Biologics License Application to the US FDA in Q1 2027. That regulatory position is the reason this page reports literature rather than issuing advice: there is no approved label to carry an alcohol warning, no prescribing information, and no clinician-facing guidance to summarise.

The country picture is in the retatrutide Philippines filing, and the regulatory background in the FDA Philippines guide. Anyone with a question about their own drinking, or about alcohol alongside any medication they are taking, should be asking a clinician rather than a search engine.

Our partner and supplier

Sourcing retatrutide for research in the Philippines

Primara Labs, our partner and supplier, lists retatrutide 15mg at PHP 3,325 a vial, or PHP 2,990 with the standing 10% off. Stock is held in Metro Manila rather than ordered in after payment, so there is no international leg on the parcel. Vials are batch-numbered, packaging is insulated and plain on the outside, same-day metro delivery applies to weekday orders confirmed before noon, and the rest of the country is one to three business days.

Buy retatrutide in the Philippines

FAQ

Is there any research on retatrutide and alcohol?